New vitamin D analogues based on the C-to-Si exchange in the side chain, along with several groups at the Si atom

Summary of the technology

This new analogues can be used to develop new drugs with antitumor action or with action on other diseases by acting on the VDR receptor with low or negligible toxic calcemic side effects. The innovative aspects are i) diminished or non-calcemic side effects and ii) slower proliferation rates of tumoral cells.

University of Porto

Details of the Technology Offer

This invention relates to the synthesis and biological applications of new vitamin D analogues based on the C-to-Si exchange in the side chain, along with several groups at the Si atom, such as alkyl, hydrogen, or hydroxyl. It is focused on i) 1,25D derivatives, ii) procedures for obtaining them, iii) their intermediates, and iv) their pharmacological applications. The new analogues can be used to develop new drugs with antitumor action or with action on other diseases by acting on the VDR receptor (psoriasis, Alzheimer's, osteoporosis, diabetes, hypertension, low immunity, rickets) with low or negligible toxic calcemic side effects.

The new analogues have a similar cell differentiation in comparison with 1,25D with diminished or non-calcemic side effects. One of the analogues is responsible for significantly increasing the weight of the animals which may suggest an increase in bone density. It was observed a slower proliferation rate of tumoral cells and a great ability to activate target genes of 1,25D for all analogues and 1,25D in comparison with the control.

Applications

Potential comercial uses/applications: Drugs - Prophylactic and/or therapeutic agent for vitamin D receptor-related diseases; Supplements - Prophylactic agent for vitamin D receptor-related diseases

Desired business relationship

Technology selling

Patent licensing

Joint ventures

Technology development

New technology applications

Adaptation of technology to other markets

Current development status

Experimental technologies

Intellectual property status

  • Patent already applied for
  • Patent application number :PCT/IB2022/052839
  • Patent already applied for
  • Patent application number :PT117825
  • Patent already applied for
  • Patent application number :P202330169

Related Keywords

  • Chemistry
  • Pharmaceutical Products / Drugs
  • Medical Health related
  • Therapeutic
  • Oncology
  • bone metabolism
  • supplementation
  • vitamin d receptors
  • d vitamin
  • 1,25d
  • 25-hydroxyvitamin d3

About University of Porto

U.Porto Innovation focuses its activities on research at the University, entrepreneurship within the academic community and U.Porto’s growing connections with industry.

Maria Antónia Nunes

Never miss an update from Maria Antónia Nunes

Create your free account to connect with Maria Antónia Nunes and thousands of other innovative organizations and professionals worldwide

Maria

Send a request for information
to Maria

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support